Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2012

Open Access 01-12-2012 | Research article

Prevalence of metabolic syndrome among patients with Schizophrenia in Palestine

Authors: Waleed M Sweileh, Sa’ed H Zyoud, Salah A Dalal, Sami Ibwini, Ansam F Sawalha, Iyad Ali

Published in: BMC Psychiatry | Issue 1/2012

Login to get access

Abstract

Background

Metabolic syndrome (MS) is a cluster of the most dangerous cardiac risk factors and is associated with high mortality. Ethnic differences in metabolic syndrome (MS) criteria and prevalence rates have been reported. The purpose of this study was to investigate the MS prevalence among patients with schizophrenia in Palestine.

Methods

We recruited 250 patients with schizophrenia from 4 psychiatric primary healthcare centers in Northern Palestine. The MS prevalence was assessed based on National Cholesterol Education Program Adult Treatment Panel III Adapted criteria.

Results

The overall MS prevalence was 43.6%, with 39% in male and 55.9% in female patients. On average, the study patients had 2.3 ± 1.3 metabolic abnormalities. Univariate analysis showed that MS was significantly higher with older age, female gender, longer duration of the illness, smoking, abdominal obesity, high systolic and diastolic blood pressure, high triglycerides, low HDL-C, and high fasting plasma glucose. Multiple logistic regression analysis showed that only systolic blood pressure, high triglycerides, high fasting plasma glucose, and low HDL-C were significant predictors of MS in schizophrenic patients.

Conclusions

MS is common among Arab patients with schizophrenia. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors.
Literature
1.
Crismon ML, Dorson PG: Schizophrenia in Pharmacotherapy: A pathophysiologic approach. Edited by: Dipiro J, Talbert RL, Yee G, Matzke GWells B, Posey L. 2002, New York: McGraw-Hill, 1219-1242. 5
2.
van Os J, et al: Prevalence of psychotic disorder and community level of psychotic symptoms: an urban–rural comparison. Arch Gen Psychiatry. 2001, 58 (7): 663-668. 10.1001/archpsyc.58.7.663.CrossRefPubMed
3.
van Os J, Kapur S: Schizophrenia. Lancet. 2009, 374 (9690): 635-645. 10.1016/S0140-6736(09)60995-8.CrossRefPubMed
4.
McGrath J, et al: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008, 30: 67-76. 10.1093/epirev/mxn001.CrossRefPubMed
5.
Sperling W, Biermann T: Mortality in patients with schizophrenia. Lancet. 2009, 374 (9701): 1592-author reply 1592–3CrossRefPubMed
6.
Tiihonen J, et al: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009, 374 (9690): 620-627. 10.1016/S0140-6736(09)60742-X.CrossRefPubMed
7.
Hennekens CH: Prevention of premature mortality among patients with schizophrenia: the need for primary prevention efforts in cardiovascular disease. CNS Spectr. 2008, 13 (6 Suppl 10): 9-10.PubMed
8.
Kelly DL, et al: Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 71 (3): 304-311.
9.
Citrome L: Metabolic syndrome and cardiovascular disease. J Psychopharmacol. 2005, 19 (6 Suppl): 84-93. 10.1177/0269881105058375.CrossRefPubMed
10.
Haffner SM, et al: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992, 41 (6): 715-722. 10.2337/diabetes.41.6.715.CrossRefPubMed
11.
Sandhofer A, et al: Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest. 2007, 37 (2): 109-116. 10.1111/j.1365-2362.2007.01751.x.CrossRefPubMed
12.
Qiao Q: Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia. 2006, 49 (12): 2837-2846.CrossRefPubMed
13.
Golley RK, et al: Comparison of metabolic syndrome prevalence using six different definitions in overweight pre-pubertal children enrolled in a weight management study. Int J Obes (Lond). 2006, 30 (5): 853-860. 10.1038/sj.ijo.0803195.CrossRef
14.
De Hert M, Peuskens B, van Winkel R: Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res. 2006, 88: 222-226. 10.1016/j.schres.2006.07.025.CrossRefPubMed
15.
Weiden PJ, Mackell JA, McDonnell DD: Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004, 66 (1): 51-57. 10.1016/S0920-9964(02)00498-X.CrossRefPubMed
16.
Lyketsos CG, et al: Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics. 2002, 43 (1): 24-30. 10.1176/appi.psy.43.1.24.CrossRefPubMed
17.
ATPIII: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106 (25): 3143-3421.
18.
Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide definition. Lancet. 2005, 366 (9491): 1059-1062. 10.1016/S0140-6736(05)67402-8.CrossRefPubMed
19.
Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998, 15 (7): 539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.CrossRefPubMed
20.
ADA: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003, 26 (Suppl 1): S5-S20.
21.
Grundy SM, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004, 44 (3): 720-732. 10.1016/j.jacc.2004.07.001.CrossRefPubMed
22.
Alberti KG, et al: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009, 120 (16): 1640-1645. 10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed
23.
Cossrow N, Falkner B: Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab. 2004, 89 (6): 2590-2594. 10.1210/jc.2004-0339.CrossRefPubMed
24.
Kraja AT, et al: An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab. 2005, 2: 17-10.1186/1743-7075-2-17.CrossRef
25.
Rakugi H, Ogihara T: The metabolic syndrome in the asian population. Curr Hypertens Rep. 2005, 7 (2): 103-109. 10.1007/s11906-005-0082-4.CrossRefPubMed
26.
Abdul-Rahim HF, et al: The metabolic syndrome in the West Bank population: an urban–rural comparison. Diabetes Care. 2001, 24 (2): 275-279. 10.2337/diacare.24.2.275.CrossRefPubMed
27.
Sirdah MM NA, Laham A, Abu Ghali AS: Prevalence of metabolic syndrome and associated socioeconomic and demographic factors among Palestinian adults (20–65 years) at the Gaza Strip. Diabetes Metab Syndr. 2011, 5 (2): 93-97. 10.1016/j.dsx.2012.02.024.CrossRefPubMed
28.
Yasein N, Masa’d D: Metabolic syndrome in family practice in Jordan: a study of high-risk groups. East Mediterr Health J. 2011, 17 (12): 943-948.PubMed
29.
Newcomer JW: Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007, 68 (Suppl 4): 8-13.PubMed
30.
Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007, 68 (Suppl 1): 20-27.PubMed
31.
Allison DB, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999, 156 (11): 1686-1696.PubMed
32.
Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003, 64 (6): 663-667. 10.4088/JCP.v64n0607.CrossRefPubMed
33.
Xiang YT, et al: Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China. Int J Clin Pharmacol Ther. 2008, 46 (5): 245-251.CrossRefPubMed
34.
Joseph D, et al: Pharmacotherapy: A pathophysiologic approach. 2011, New York, NY: The McGraw - Hill Companies, 1147-1172. 8
35.
Chinn S: A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000, 19 (22): 3127-3131. 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M.CrossRefPubMed
36.
Cohn T, et al: Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004, 49 (11): 753-760.PubMed
37.
De Hert M, et al: Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006, 2: 14-10.1186/1745-0179-2-14.CrossRefPubMedPubMedCentral
38.
De Hert MA, et al: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006, 83 (1): 87-93. 10.1016/j.schres.2005.12.855.CrossRefPubMed
39.
Hagg S, et al: High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006, 21 (2): 93-98. 10.1097/01.yic.0000188215.84784.17.CrossRefPubMed
40.
McEvoy JP, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005, 80 (1): 19-32. 10.1016/j.schres.2005.07.014.CrossRefPubMed
41.
Suvisaari JM, et al: Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry. 2007, 68 (7): 1045-1055. 10.4088/JCP.v68n0711.CrossRefPubMed
42.
Hatata H, et al: Risk of metabolic syndrome among Egyptian patients with schizophrenia. Current Psychiatry. 2009, 16 (1): 85-95.
43.
Shahda M, Elsayed O, El-Boraie A: Study of the prevalence of metabolic syndrome among psychiatric patients and its correlation with diagnosis and medications Egypt. J. Psychiatry. 2010, 31 (2): 17-24.
44.
De Hert M, et al: Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008, 101 (1–3): 295-303.CrossRefPubMed
45.
Meyer JM, et al: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008, 101 (1–3): 273-286.CrossRefPubMedPubMedCentral
46.
Correll CU, et al: Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res. 2007, 89 (1–3): 91-100.CrossRefPubMed
47.
Mackin P, Watkinson HM, Young AH: Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005, 48 (2): 215-221. 10.1007/s00125-004-1641-y.CrossRefPubMed
48.
Thakore JH, et al: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002, 26 (1): 137-141. 10.1038/sj.ijo.0801840.CrossRefPubMed
49.
Mukherjee S, Schnur DB, Reddy R: Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989, 1 (8636): 495-CrossRefPubMed
50.
Wilson PW, et al: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005, 112 (20): 3066-3072. 10.1161/CIRCULATIONAHA.105.539528.CrossRefPubMed
51.
Wilson PW, et al: Prediction of coronary heart disease using risk factor categories. Circulation. 1998, 97 (18): 1837-1847. 10.1161/01.CIR.97.18.1837.CrossRefPubMed
52.
Metadata
Title
Prevalence of metabolic syndrome among patients with Schizophrenia in Palestine
Authors
Waleed M Sweileh
Sa’ed H Zyoud
Salah A Dalal
Sami Ibwini
Ansam F Sawalha
Iyad Ali
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2012
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-12-235

Other articles of this Issue 1/2012

BMC Psychiatry 1/2012 Go to the issue

Research article

Bipolar disorders and Wilson’s disease

Research article

Anxiety symptoms among Chinese nurses and the associated factors: a cross sectional study

Research article

Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status

Study protocol

Effect of depression on mortality and cardiovascular morbidity in type 2 diabetes mellitus after 3 years follow up. The DIADEMA study protocol

Research article

Glucocorticoid receptor mRNA and protein isoform alterations in the orbitofrontal cortex in schizophrenia and bipolar disorder

Research article

Prognostic significance of functional somatic symptoms in adolescence: a 15-year community-based follow-up study of adolescents with depression compared with healthy peers